Nasdaq (NMTC): Q1 & Q2 Product Revenue Growth And A Key Launch Could Spark Breakout Buzz

Under the radar right now, we're highlighting a Nasdaq past champ that needs immediate attention. Nasdaq (NMTC): Q1 & Q2 Product Revenue Growth And A Key Launch Could Spark Breakout Buzz May 24th Dear Reader, Under the radar right now, we're highlighting a Nasdaq past champ that needs immediate attention. Alerted previously based on its breakout potential, this profile has exploded for approximate $1.00+ short term runs on multiple occasions! That's the kind of unruly moves you'll see when a low float profile takes the main stage. And with fewer than 20Mn shares in its float according to [Yahoo Finance]( you need to be on the lookout for significant volatility when other potential catalysts, like positive company news, presents itself. With the recent announcement of product revenue growth of over 100% [in fiscal Q2 2024]( in comparison to Q2 2023, this company looks determined to disrupt a multi-Bn market opportunity. Oh, yeah. That's on top of major Q1 product revenue growth, [too!]( It gets better... [A recent product launch]( could start raising eyebrows as this Nasdaq profile looks to make the leap from the minors to the major leagues in 2024. Drop everything right now and pull up: *NeuroOne Medical Technologies Corporation (NMTC)* NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. And based on multiple potential breakout catalysts, NMTC could be on course for a major spark. Check these out: No. 1 - Product Revenue Surges In Fiscal Q2 While Complete Corporate Update Shines. No. 2 - Volatility Potential Looms As NMTC's Low Float Could Create The Environment For An Explosive Scenario. No. 3 - First To Market With Game-Changing Tech Could Put NMTC On Wall Street's Watch-list. No. 4 - Commercial Launch Of OneRF™ Acts As Significant Milestone For This Company On The Rise. But more on those in a second... Neurological Disorders - The Next Frontier In Medicine There is a growing epidemic of neurological disorders: epilepsy, Parkinson’s Disease, chronic back pain, depression, essential tremors etc. A lack of innovation in electrode technology has slowed insights and progress toward better treatment alternatives. NeuroOne has developed a breakthrough thin-film electrode. Electrode Technology Value Proposition Highly Disruptive Thin-Film Technology with Superior Competitive Advantages Thin-Film & Flexibility - Highly flexible design provides new options for surgical placement and potentially smaller borings/incisions - Lower inflammation compared to bulkier electrodes Combination Device - Enables pairing of diagnostic and therapeutic into combination product - Potential to be used in an MRI machine - current electrodes can’t be used in MRI - Potential to eliminate an entire surgical procedure and improve outcomes Precision - Ultra High-definition technology increases signal clarity via lower impedance (noise) - May enable ablation or stimulation of the targeted tissue with better precision - May have ability to detect micro-seizures and treat prior to seizure progression Cost & Manufacturing - Cost competitive to current electrode technology - Fast fulfillment – automated / scalable process - High reliability – no soldering / consistent manufacturing process Evo® Cortical Electrode OneRF(TM): A Sure Step in Patient Care OneRF(TM) is one minimally-invasive step that could help eliminate prognostic uncertainty and potentially reduce seizures. A sure step in patient care. OneRF(TM) is the First and Only FDA-cleared sEEG-RF System It provides bedside monitoring, mapping and ablation, giving physicians a less invasive, potentially safer way to gain improved bedside clarity of the therapeutic window for an epilepsy patient with the possibility of seizure reduction or freedom. Indications for Use: The NeuroOne OneRF™ Radiofrequency Ablation System is indicated for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures. (FDA Clearance: K231675) OneRF(TM) Is A Critical Step In The Epilepsy Care Pathway It may allow for better understanding of the therapeutic window, keeping physicians on the path to prognostic clarity and treatment possibility. Gives Patients Uninterrupted, Less-Invasive Care Keep patients on the path to seizure freedom with a minimally-invasive step, bedside, without care interruption. - May Reduce Seizures - Potential for Seizure Freedom - May Avoid Additional Potential Invasive Surgeries Sources: [NMTC Presentation.]( [NMTC Website.]( ----- And based on multiple potential catalysts, NMTC requires full focus again. Take a look: No. 1 NMTC Potential Catalyst - Product Revenue Surges In Fiscal Q2 While Complete Corporate Update Shines. NeuroOne® Reports Second Quarter Fiscal Year 2024 Fi-nan-cial Results and Provides Corporate Update EDEN PRAIRIE, Minn., May 14, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the second quarter fiscal year 2024 ended March 31, 2024. Second Quarter Fiscal Year 2024 and Recent Business Updates Financial Highlights: - Product revenue of $1.377Mn in Q2 2024, compared to $466k in Q2 2023 - Raised an additional $2.0Mn using the ATM Program in Q2 2024 Evo® sEEG: - Zimmer Biomet continued to expand into new accounts - Product exhibited by Zimmer Biomet at the American Association of Neurological Surgeons (AANS) in May OneRF™ Ablation System: - Completed site training and initiated limited commercial launch of the OneRF™ Ablation System in late March - Successfully implanted five patients - Completed initial manufacturing run for limited commercial launch - Presented ICD-10-PCS hospital inpatient code application to the Centers for Medicare and Medicaid Services (CMS) in March for the OneRF™ ablation procedure to support accurate data collection and processing of reimbursement claims by hospitals for the ablation procedure - Exhibited the OneRF™ Ablation System at the AANS meeting in May ... [Read the full article here.]( ----- No. 2 NMTC Potential Catalyst - Volatility Potential Looms As NMTC's Low Float Could Create The Environment For An Explosive Scenario. According to the [Yahoo Finance]( website, NMTC has a low float. The website reports this profile to have approximately 19.52Mn shares in its float. Why is that important? It's important on one crucial level. Volatility. Could more positive company news in mid-2024 provide a near term spark? ----- No. 3 NMTC Potential Catalyst - First To Market With Game-Changing Tech Could Put NMTC On Wall Street's Watch-list. NeuroOne® Announces First Implant of OneRF™ Ablation Electrodes First to market FDA-cleared thin-film, sEEG-guided RF system capable of both recording electrical activity and ablating nervous tissue with the added benefit of temperature control EDEN PRAIRIE, Minn., April 09, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), ..., today announced the first implant of its OneRF™ Ablation electrode by doctors at a top ranked hospital in the US, as ranked by the US News & World Best Hospital Report in its 2023-2024 publication. The OneRF™ Ablation system has FDA 510(k) clearance for creation of radiofrequency (“RF”) lesions in nervous tissue for functional neurosurgical procedures. “We are excited to announce that yesterday, doctors implanted Evo® sEEG-RF electrodes in a patient suffering from epilepsy. Once the monitoring identifies the areas of the brain that are causing seizures, the surgical team now has the option to use the same electrodes to perform an ablation utilizing NeuroOne’s RF generator. This capability provides the neurosurgeon an entirely new option for use in the appropriate patients and situation. Being first to market with this technology positions the Company as a market leader in offering multi-functional diagnostic and therapeutic thin-film electrode technology,” said Dave Rosa, CEO of NeuroOne. “As stated previously, we believe the technology has the potential to reduce hospital stays, number of surgeries, and adverse events, while offering significant clinical benefits including temperature control to enhance patient safety.” ... [Read the full article here.]( ----- No. 4 NMTC Potential Catalyst - Commercial Launch Of OneRF™ Acts As Significant Milestone For This Company On The Rise. NeuroOne® Initiates Limited Commercial Launch of OneRF™ Ablation System First to market FDA-cleared thin-film, sEEG-guided RF system capable of both recording electrical activity and ablating nervous tissue with the added benefit of temperature control Limited commercial launch initiated earlier than expected EDEN PRAIRIE, Minn., March 26, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), ..., today announced that it has initiated a limited commercial launch of its OneRF™ Ablation System, which has FDA 510(k) clearance for creation of radiofrequency (“RF”) lesions in nervous tissue for functional neurosurgical procedures. “Today is an exciting day for NeuroOne as we begin the limited commercial launch of our OneRF™ Ablation System. We are proud to be the first to market with a thin-film electrode technology capable of performing both diagnostic and therapeutic functions utilizing the same electrode,” said Dave Rosa, CEO of NeuroOne. “We expect to start shipping systems this week to centers participating in our limited launch with cases already scheduled starting in April. We believe physicians and patients will benefit from our technology given it may reduce hospital stays, number of surgeries, and adverse events, while offering significant clinical benefits including temperature control to enhance patient safety. Looking ahead, we plan to leverage the system for other targeted ablation indications by submitting additional FDA 510(k) applications.” ... [Read the full article here.]( ----- NMTC Recap - 4 Must-Know Potential Breakout Catalysts No. 1 - Product Revenue Surges In Fiscal Q2 While Complete Corporate Update Shines. No. 2 - Volatility Potential Looms As NMTC's Low Float Could Create The Environment For An Explosive Scenario. No. 3 - First To Market With Game-Changing Tech Could Put NMTC On Wall Street's Watch-list. No. 4 - Commercial Launch Of OneRF™ Acts As Significant Milestone For This Company On The Rise. ----- Coverage is officially reinitiated on (Nasdaq: NMTC). Get this breakout idea on your screen now. When there are updates, I'll get them out quickly. Talk soon. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Ownership of FI has now moved to a single individual. Disclosure: I am not a lic-ensed fina-ncial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Fierce full disclosure is to be read and fully understood before using Fierce's website, or joining Fierce's email or text list. By viewing Fierce's website and/or reading Fierce's email or text newsletter you are agreeing to -> [( An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates stockwirenews . com (“SWN”), and owns and operates stockstreetwire . com ("SSW"). From time to time, SWN, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SWN Media LLC and TD Media LLC, StockWireNews has been hired for a period beginning on 8/7/22 and ending on 8/9/22 to publicly disseminate information about (NMTC) via Website, Email and SMS. SWN Media LLC was paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (NMTC). Pursuant to an agreement between SWN Media LLC and Legends Media LLC, FierceInvestor (FI) has been hired for a period beginning on 11/20/22 and ending on 11/21/22 to publicly disseminate information about (NMTC) via Website, Email and SMS. SWN Media LLC was paid seventeen thousand USD via bank wire transfer. We own zero shares of (NMTC). Pursuant to an agreement between SWN Media LLC and Legends Media LLC, FierceInvestor (FI) has been hired for a period beginning on 3/6/23 and ending on 3/7/23 to publicly disseminate information about (NMTC) via Website, Email and SMS. SWN Media LLC was paid two thousand five hundred USD via bank wire transfer. We own zero shares of (NMTC). Pursuant to an agreement between SWN Media LLC and TD Media LLC, FierceInvestor (FI) has been hired for a period beginning on 7/9/23 and ending on 7/11/23 to publicly disseminate information about (NMTC) via Website, Email and SMS. SWN Media LLC was paid seventeen thousand five hundred USD via bank wire transfer. We own zero shares of (NMTC). Pursuant to an agreement between SWN Media LLC and TD Media LLC, FierceInvestor (FI) has been hired for a period beginning on 10/16/23 and ending on 10/17/23 to publicly disseminate information about (NMTC) via Website, Email and SMS. SWN Media LLC was paid twenty thousand USD via bank wire transfer. We own zero shares of (NMTC). To date we have been compensated a total of eighty-two thousand five hundred USD via bank wire transfer to disseminate information about (NMTC). SWN Media LLC has not been compensated for today's profile on (NMTC). We own zero shares of (NMTC). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and Sica Media LLC, TD Media LLC has been hired for a period beginning on 05/7/2024 and ending on 05/7/2024 to publicly disseminate information about (NMTC:US) via digital communications. We have been paid an additional twelve thousand five hundred USD. To date we have been paid five hundred eighty five thousand two hundred fifty USD to disseminate information about (NMTC:US) via digital communications. We own zero shares of (NMTC:US). TD Media LLC has not been compensated for today’s (05/24/2024) profile on (NMTC:US) and we own zero shares of (NMTC:US). Fierce | 4834 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US [Unsubscribe]( | [Update Profile]( | [Constant Contact Data Notice](